

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM424996

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Navidea Biopharmaceuticals, Inc.		03/03/2017	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Cardinal Health 414, LLC		
<b>Street Address:</b>	7000 Cardinal Place		
<b>City:</b>	Dublin		
<b>State/Country:</b>	OHIO		
<b>Postal Code:</b>	43017		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3163525	LYMPHOSEEK	
<b>Registration Number:</b>	4800275	LYMPHOSEEK (TECHNETIUM TC 99M TILMANOCEP)	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2028576395		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	202.350.3663		
<b>Email:</b>	tammy.mitchell@arentfox.com		
<b>Correspondent Name:</b>	N. Christopher Norton		
<b>Address Line 1:</b>	1717 K St NW		
<b>Address Line 2:</b>	Arent Fox LLP		
<b>Address Line 4:</b>	Washington, D.C. 20006		
<b>ATTORNEY DOCKET NUMBER:</b>	032828.01651 / 01657		
<b>NAME OF SUBMITTER:</b>	N. Christopher Norton		
<b>SIGNATURE:</b>	/N. Christopher Norton/		
<b>DATE SIGNED:</b>	04/25/2017		
<b>Total Attachments: 6</b>			
source=NAI_1502532830_1_Trademark Assignment#page1.tif			
source=NAI_1502532830_1_Trademark Assignment#page2.tif			

OP \$65.00 3163525

source=NAI\_1502532830\_1\_Trademark Assignment#page3.tif

source=NAI\_1502532830\_1\_Trademark Assignment#page4.tif

source=NAI\_1502532830\_1\_Trademark Assignment#page5.tif

source=NAI\_1502532830\_1\_Trademark Assignment#page6.tif

Trademark Assignment

This TRADEMARK ASSIGNMENT, dated as of March 3, 2017 (this "Trademark Assignment"), is executed and delivered by Navidea Biopharmaceuticals, Inc., a Delaware corporation ("Assignor"), in favor of Cardinal Health 414, LLC, a Delaware limited liability company ("Assignee").

**RECITALS**

A. Assignor and Assignee entered into that certain Asset Purchase Agreement, dated as of November 23, 2016 (the "Asset Purchase Agreement"), pursuant to which, at the Closing, Assignor has agreed to sell, transfer, convey and assign to Assignee, and Assignee has agreed to purchase and assume from Seller, Assignor's worldwide right, title and interest in, to and under, along with other Acquired Assets, the trademarks, trade names, service marks, certification marks, service names, brands, trade dress and logos set forth on Schedule A hereto, together with the goodwill associated therewith and all registrations thereof, applications therefor and renewals and extensions thereof (hereinafter collectively referred to as the "Trademarks");

B. In accordance with the Asset Purchase Agreement, Assignor desires to sell, transfer, convey and assign to Assignee, and Assignee desires to purchase and assume all of Assignor's worldwide right, title and interest in, to and under the Trademarks;

C. Capitalized terms used herein without definition shall have the respective meanings set forth in the Asset Purchase Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and with the intent to be legally bound hereby, Assignor and Assignee agree as follows:

AGREEMENT

Assignor hereby sells, transfers, conveys and assigns to Assignee, its successors and assigns all of Assignor's right, title and interest in, to and under the Trademarks and all the rights appurtenant thereto, together with the goodwill associated therewith and which is symbolized thereby, all of Assignor's rights and actions for past infringement and/or misappropriation, and any and all renewals and extensions thereof that may hereafter be secured under the Legal Requirements now or hereafter in effect in the United States and in any other jurisdiction, all to be held and enjoyed by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this Trademark Assignment not been made.

Assignee agrees to execute and deliver, or cause to be executed and delivered, such further instruments and take such other actions as Assignee or Assignor may deem reasonably necessary to record the assignment of the Trademarks to Assignee as contemplated by this Trademark Assignment or to secure for Assignee or its successors or assigns, or to evidence the rights, hereby transferred.

Assignor authorizes and requests that the United States Commissioner of Patents and Trademarks and any other similar government authority to record Assignee as owner of the

Trademarks and issue any and all trademarks issued thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee and its successors, assigns or other legal representatives. Assignee shall have the right to record this Trademark Assignment with all applicable government authorities and registrars so as to perfect its ownership of the Trademarks.

This Trademark Assignment shall inure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns.

This Trademark Assignment may be executed in two or more counterparts for the convenience of the parties, each of which will be deemed an original and all of which together will constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Trademark Assignment by facsimile or portable document format will be effective as delivery of a manually executed counterpart to this Trademark Assignment.


This Trademark Assignment will be governed by, and construed in accordance with, the internal Legal Requirements of the State of Delaware, without reference to the choice of Legal Requirement or conflict of Legal Requirements principles thereof. The parties hereby agree and consent to be subject to the exclusive jurisdiction of the courts of Delaware, and hereby waive the right to assert the lack of personal or subject matter jurisdiction or improper venue in connection with any such Action.

This Trademark Assignment is being executed and delivered pursuant to Section 2.9(a) of the Asset Purchase Agreement and is not intended to in any way supersede, amend, expand, waive or otherwise modify or affect the rights and obligations of the parties under the Asset Purchase Agreement.

*[signature page follows]*

IN WITNESS WHEREOF, Assignor and Assignee have caused this Trademark Assignment to be executed as of the date first written above.

**NAVIDEA BIOPHARMACEUTICALS, INC.**

By:   
Name: Jed A. Latkin  
Title: Interim Chief Financial Officer/Chief Operating Officer

**CARDINAL HEALTH 414, LLC**

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

[Signature Page to Trademark Assignment]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Trademark Assignment to be executed as of the date first written above.

NAVIDEA BIOPHARMACEUTICALS, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

CARDINAL HEALTH 414, LLC

By: Tiffany Olson  
Name: Tiffany Olson  
Title: President - Nuclear Pharmacy Services

[Signature Page to Trademark Assignment]

Schedule A  
Trademarks

Mark	Country	Serial No.	Class No(s).	Filing Date	Registration No.	Registration Date
LYMPHOSEEK ® (Text Only)	Int'l Registration - Madrid Protocol Only	A0054397	5	11/5/2015	1,280,196	11/5/2015
	Australia	A0054397	5	11/5/2015	1,280,196	11/5/2015
	New Zealand	A0054397	5	11/5/2015	1,280,196	11/5/2015
	Norway	A0054397	5	11/5/2015	1,280,196	11/5/2015
	Switzerland	A0054397	5	11/5/2015	1,280,196	11/5/2015
	USA	78/419,919	5	5/17/2004	3,163,525	10/24/2006
	Canada	1647184	5	10/9/2013	TMA924041	12/18/2015
	European Community	12204202	5	10/31/2013	12,204,202	3/5/2014
	Iceland	1294611	5	3/1/2016	1,294,611	3/1/2016
	Japan		5		5,649,575	2/14/2014
	China	13988394	5	1/27/2014	13,988,394	4/21/2015
	USA	86/055,675	5	9/4/2013	4800275	8/25/2015

Copyright

Title	Full Title	Copyright Number	Date
Neoprobe Corporation Product Pipeline -- Oncology Diagnostic Drugs.	Neoprobe Corporation Product Pipeline -- Oncology Diagnostic Drugs.	TX0007400138	2010

4846-0604-8324, v. 1  
NAI-1502532791v1